palbociclib (BioDeep_00000858516)
代谢物信息卡片
palbociclib
化学式: C24H29N7O2 (447.2382614)
中文名称: 帕布昔利布
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=C(C(=O)N(C2=NC(=NC=C12)NC3=NC=C(C=C3)N4CCNCC4)C5CCCC5)C(=O)C
InChI: InChI=1S/C24H29N7O2/c1-15-19-14-27-24(28-20-8-7-18(13-26-20)30-11-9-25-10-12-30)29-22(19)31(17-5-3-4-6-17)23(33)21(15)16(2)32/h7-8,13-14,17,25H,3-6,9-12H2,1-2H3,(H,26,27,28,29)
描述信息
L - Antineoplastic and immunomodulating agents > L01 - Antineoplastic agents > L01E - Protein kinase inhibitors > L01EF - Cyclin-dependent kinase (cdk) inhibitors
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor
C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C2185 - Cyclin-Dependent Kinase Inhibitor
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials
C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors
C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent
D000970 - Antineoplastic Agents
Corona-virus
Coronavirus
SARS-CoV-2
COVID-19
SARS-CoV
COVID19
SARS2
SARS
同义名列表
1 个代谢物同义名
数据库引用编号
6 个数据库交叉引用编号
- ChEBI: CHEBI:85993
- KEGGdrug: D10372
- PubChem: 5330286
- DrugBank: DB09073
- ChEMBL: CHEMBL189963
- CAS: 571190-30-2
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Henriëtte M G Willems, Simon Edwards, Helen K Boffey, Stephen J Chawner, Christopher Green, Tamara Romero, David Winpenny, John Skidmore, Jonathan H Clarke, Stephen P Andrews. Identification of ARUK2002821 as an isoform-selective PI5P4Kα inhibitor.
RSC medicinal chemistry.
2023 May; 14(5):934-946. doi:
10.1039/d3md00039g. [PMID: 37252102] - Po-Jen Chen, Hsin-Hui Tseng, Yi-Hsuan Wang, Shu-Yen Fang, Shun-Hua Chen, Chun-Hong Chen, Sheng-Chieh Tsai, Yu-Chia Chang, Yung-Fong Tsai, Tsong-Long Hwang. Palbociclib blocks neutrophilic PI3K activity to alleviate psoriasiform dermatitis.
British journal of pharmacology.
2023 Mar; ?(?):. doi:
10.1111/bph.16080. [PMID: 36967633] - Tomoyasu Fujii, Jun Kamishikiryo, Tetsuo Morita. Palbociclib regulates intracellular lipids in mammary tumor cells by secreting lipoprotein lipase.
Pharmacological reports : PR.
2022 Jun; 74(3):503-512. doi:
10.1007/s43440-022-00365-0. [PMID: 35366749] - Aneesha Polisety, Gauri Misra, Jyotika Rajawat, Amit Katiyar, Harpreet Singh, Anant Narayan Bhatt. Therapeutic natural compounds Enzastaurin and Palbociclib inhibit MASTL kinase activity preventing breast cancer cell proliferation.
Medical oncology (Northwood, London, England).
2022 May; 39(5):100. doi:
10.1007/s12032-022-01701-3. [PMID: 35599277] - Luca Malorni, Svitlana Tyekucheva, Florentine S Hilbers, Michail Ignatiadis, Patrick Neven, Marco Colleoni, Stéphanie Henry, Alberto Ballestrero, Andrea Bonetti, Guy Jerusalem, Konstantinos Papadimitriou, Antonio Bernardo, Elena Seles, Francois P Duhoux, Iain R MacPherson, Alastair Thomson, David Mark Davies, Mattias Bergqvist, Ilenia Migliaccio, Géraldine Gebhart, Gabriele Zoppoli, Judith M Bliss, Matteo Benelli, Amelia McCartney, Roswitha Kammler, Heidi De Swert, Barbara Ruepp, Debora Fumagalli, Rudolf Maibach, David Cameron, Sherene Loi, Martine Piccart, Meredith M Regan. Serum thymidine kinase activity in patients with hormone receptor-positive and HER2-negative metastatic breast cancer treated with palbociclib and fulvestrant.
European journal of cancer (Oxford, England : 1990).
2022 03; 164(?):39-51. doi:
10.1016/j.ejca.2021.12.030. [PMID: 35172272] - Laura Molenaar-Kuijsten, C Louwrens Braal, Stefanie L Groenland, Niels de Vries, Hilde Rosing, Jos H Beijnen, Stijn L W Koolen, Annelie J E Vulink, Marloes G J van Dongen, Ron H J Mathijssen, Alwin D R Huitema, Neeltje Steeghs. Effects of the Moderate CYP3A4 Inhibitor Erythromycin on the Pharmacokinetics of Palbociclib: A Randomized Crossover Trial in Patients With Breast Cancer.
Clinical pharmacology and therapeutics.
2022 02; 111(2):477-484. doi:
10.1002/cpt.2455. [PMID: 34674222] - Nan-Nan Chu, Lin Zhang, Jiakun Wang, Xianghong Gu, Ying Ding, Kai Huang, Lin-Ling Que, Qing He. Bioequivalence Study of Palbociclib Capsules in Healthy Chinese Subjects Under Fasting and Fed Conditions.
Clinical drug investigation.
2022 Jan; 42(1):53-63. doi:
10.1007/s40261-021-01103-9. [PMID: 34837169] - Zhengchao Shen, Jian Wang, Kunbin Ke, Rong Chen, Aixue Zuo, Rongping Zhang, Weiping Wan, Xingxing Xie, Xuhua Li, Na Song, Hao Fu, Zhiwei Zhang, Enli Cai, Jihong Shen, Qingyu Zhang, Xinan Shi. Polyphyllin I, a lethal partner of Palbociclib, suppresses non-small cell lung cancer through activation of p21/CDK2/Rb pathway in vitro and in vivo.
Cell cycle (Georgetown, Tex.).
2021 12; 20(23):2494-2506. doi:
10.1080/15384101.2021.1991121. [PMID: 34658297] - Ariana Soledad Poetto, Bianca Posocco, Sara Gagno, Marco Orleni, Martina Zanchetta, Valentina Iacuzzi, Giovanni Canil, Mauro Buzzo, Marcella Montico, Michela Guardascione, Debora Basile, Giacomo Pelizzari, Martina Alberti, Lorenzo Gerratana, Fabio Puglisi, Giuseppe Toffoli. A new dried blood spot LC-MS/MS method for therapeutic drug monitoring of palbociclib, ribociclib, and letrozole in patients with cancer.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2021 Nov; 1185(?):122985. doi:
10.1016/j.jchromb.2021.122985. [PMID: 34700133] - Fanny Leenhardt, Marie Alexandre, Severine Guiu, Stephane Pouderoux, Melanie Beaujouin, Gerald Lossaint, Laurent Philibert, Alexandre Evrard, William Jacot. Impact of pharmacist consultation at clinical trial inclusion: an effective way to reduce drug-drug interactions with oral targeted therapy.
Cancer chemotherapy and pharmacology.
2021 10; 88(4):723-729. doi:
10.1007/s00280-021-04331-0. [PMID: 34286354] - Binghe Xu, Huiping Li, Qingyuan Zhang, Wan Sun, Yanke Yu, Wei Li, Shusen Wang, Ning Liao, Peng Shen, Yuan Liu, Yaling Huang, Carlos Linn, Huadong Zhao, John Jiang, Diane Wang. Pharmacokinetics, safety, activity, and biomarker analysis of palbociclib plus letrozole as first-line treatment for ER+/HER2- advanced breast cancer in Chinese women.
Cancer chemotherapy and pharmacology.
2021 07; 88(1):131-141. doi:
10.1007/s00280-021-04263-9. [PMID: 33835229] - Lilibeth Lanceta, Nadiia Lypova, Conor O'Neill, Xiaohong Li, Eric Rouchka, Jason Chesney, Yoannis Imbert-Fernandez. Differential gene expression analysis of palbociclib-resistant TNBC via RNA-seq.
Breast cancer research and treatment.
2021 Apr; 186(3):677-686. doi:
10.1007/s10549-021-06127-5. [PMID: 33599863] - Lauren Darrigues, Jean-Yves Pierga, Alice Bernard-Tessier, Ivan Bièche, Amanda Bartolini Silveira, Marc Michel, Delphine Loirat, Paul Cottu, Luc Cabel, Coraline Dubot, Romain Geiss, Francesco Ricci, Anne Vincent-Salomon, Charlotte Proudhon, François-Clément Bidard. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients.
Breast cancer research : BCR.
2021 03; 23(1):31. doi:
10.1186/s13058-021-01411-0. [PMID: 33676547] - Ben O'Leary, Rosalind J Cutts, Xin Huang, Sarah Hrebien, Yuan Liu, Fabrice André, Sibylle Loibl, Sherene Loi, Isaac Garcia-Murillas, Massimo Cristofanilli, Cynthia Huang Bartlett, Nicholas C Turner. Circulating Tumor DNA Markers for Early Progression on Fulvestrant With or Without Palbociclib in ER+ Advanced Breast Cancer.
Journal of the National Cancer Institute.
2021 03; 113(3):309-317. doi:
10.1093/jnci/djaa087. [PMID: 32940689] - Tingting Chen, Liu Liu, Yonghong Zou, Xiaoyan Hu, Wenfeng Zhang, Tao Zhou, Xi Luo, Weihua Fu, Jie Xu. Nobiletin downregulates the SKP2-p21/p27-CDK2 axis to inhibit tumor progression and shows synergistic effects with palbociclib on renal cell carcinoma.
Cancer biology & medicine.
2021 02; 18(1):227-244. doi:
10.20892/j.issn.2095-3941.2020.0186. [PMID: 33628597] - Nadia Harbeck. Risk-adapted adjuvant therapy of luminal early breast cancer in 2020.
Current opinion in obstetrics & gynecology.
2021 02; 33(1):53-58. doi:
10.1097/gco.0000000000000679. [PMID: 33337614] - Jing Li, Jun Jiang, Jianmei Wu, Xun Bao, Nader Sanai. Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment.
Clinical pharmacology and therapeutics.
2021 02; 109(2):494-506. doi:
10.1002/cpt.2021. [PMID: 32799335] - Tara Akhshi, William S Trimble. A non-canonical Hedgehog pathway initiates ciliogenesis and autophagy.
The Journal of cell biology.
2021 01; 220(1):. doi:
10.1083/jcb.202004179. [PMID: 33258871] - Javier Pascual, Joline S J Lim, Iain R Macpherson, Anne C Armstrong, Alistair Ring, Alicia F C Okines, Rosalind J Cutts, Maria Teresa Herrera-Abreu, Isaac Garcia-Murillas, Alex Pearson, Sarah Hrebien, Heidrun Gevensleben, Paula Z Proszek, Michael Hubank, Margaret Hills, Jenny King, Mona Parmar, Toby Prout, Laura Finneran, Jason Malia, Karen E Swales, Ruth Ruddle, Florence I Raynaud, Alison Turner, Emma Hall, Timothy A Yap, Juanita S Lopez, Nicholas C Turner. Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers.
Cancer discovery.
2021 01; 11(1):92-107. doi:
10.1158/2159-8290.cd-20-0553. [PMID: 32958578] - Liuwei Huang, Yanting Shen, Chongbin Liu, Caizhen Li, Jun Wang. [Palbociclib induces cell cycle arrest and senescence of human renal tubular epithelial cells in vitro].
Nan fang yi ke da xue xue bao = Journal of Southern Medical University.
2020 Dec; 40(12):1784-1792. doi:
10.12122/j.issn.1673-4254.2020.12.13. [PMID: 33380388] - Jeremiah D Momper, Jin Yang, Janice Kerr, Ila Saunders, Jennifer Smith, Mita M Shah. Interaction Between Cyclosporine and Palbociclib in a Renal Transplant Patient: Case Report and Pharmacokinetic Perspective.
Journal of pharmacy practice.
2020 Dec; 33(6):912-914. doi:
10.1177/0897190019851887. [PMID: 31248333] - Yanke Yu, Justin Hoffman, Anna Plotka, Melissa O'Gorman, Haihong Shi, Diane Wang. Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function.
Cancer chemotherapy and pharmacology.
2020 12; 86(6):701-710. doi:
10.1007/s00280-020-04163-4. [PMID: 33037918] - Stefanie L Groenland, Alejandra Martínez-Chávez, Marloes G J van Dongen, Jos H Beijnen, Alfred H Schinkel, Alwin D R Huitema, Neeltje Steeghs. Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib.
Clinical pharmacokinetics.
2020 12; 59(12):1501-1520. doi:
10.1007/s40262-020-00930-x. [PMID: 33029704] - Luc Cabel, Dan Rosenblum, Florence Lerebours, Etienne Brain, Delphine Loirat, Mattias Bergqvist, Paul Cottu, Anne Donnadieu, Anne Bethune, Nicolas Kiavue, Manuel Rodrigues, Jean-Yves Pierga, Marie-Laure Tanguy, François-Clément Bidard. Plasma thymidine kinase 1 activity and outcome of ER+ HER2- metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Breast cancer research : BCR.
2020 09; 22(1):98. doi:
10.1186/s13058-020-01334-2. [PMID: 32928264] - Hui Jiang, Ningning Luo, Xing Zhang, Chao Song, Jianhua Zang. EGFR L861Q and CDK4 amplification responding to afatinib combined with palbociclib treatment in a patient with advanced lung squamous cell carcinoma.
Lung cancer (Amsterdam, Netherlands).
2020 07; 145(?):216-218. doi:
10.1016/j.lungcan.2020.04.001. [PMID: 32345450] - Vaishnavi Sundar, Ramasamy Tamizhselvi. Inhibition of Rb phosphorylation leads to H2S-mediated inhibition of NF-kB in acute pancreatitis and associated lung injury in mice.
Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].
2020 Jun; 20(4):647-658. doi:
10.1016/j.pan.2020.04.011. [PMID: 32402695] - Amelia McCartney, Martina Bonechi, Francesca De Luca, Chiara Biagioni, Giuseppe Curigliano, Erica Moretti, Alessandro Marco Minisini, Mattias Bergqvist, Matteo Benelli, Ilenia Migliaccio, Francesca Galardi, Emanuela Risi, Irene De Santo, Dario Romagnoli, Laura Biganzoli, Angelo Di Leo, Luca Malorni. Plasma Thymidine Kinase Activity as a Biomarker in Patients with Luminal Metastatic Breast Cancer Treated with Palbociclib within the TREnd Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2020 05; 26(9):2131-2139. doi:
10.1158/1078-0432.ccr-19-3271. [PMID: 31937617] - Emmanuelle Jeannot, Lauren Darrigues, Marc Michel, Marc-Henri Stern, Jean-Yves Pierga, Aurore Rampanou, Samia Melaabi, Camille Benoist, Ivan Bièche, Anne Vincent-Salomon, Radouane El Ayachy, Aurélien Noret, Nicolas Epaillard, Luc Cabel, François-Clément Bidard, Charlotte Proudhon. A single droplet digital PCR for ESR1 activating mutations detection in plasma.
Oncogene.
2020 04; 39(14):2987-2995. doi:
10.1038/s41388-020-1174-y. [PMID: 32042112] - Bianca Posocco, Mauro Buzzo, Ariana Soledad Poetto, Marco Orleni, Sara Gagno, Martina Zanchetta, Valentina Iacuzzi, Michela Guardascione, Fabio Puglisi, Debora Basile, Giacomo Pelizzari, Elena Marangon, Giuseppe Toffoli. Simultaneous quantification of palbociclib, ribociclib and letrozole in human plasma by a new LC-MS/MS method for clinical application.
PloS one.
2020; 15(2):e0228822. doi:
10.1371/journal.pone.0228822. [PMID: 32032379] - Marzia Del Re, Ilaria Bertolini, Stefania Crucitta, Lorenzo Fontanelli, Eleonora Rofi, Claudia De Angelis, Lucrezia Diodati, Diletta Cavallero, Giulia Gianfilippo, Barbara Salvadori, Stefano Fogli, Alfredo Falcone, Cristian Scatena, Antonio Giuseppe Naccarato, Manuela Roncella, Matteo Ghilli, Riccardo Morganti, Andrea Fontana, Romano Danesi. Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients.
Breast cancer research and treatment.
2019 Nov; 178(1):57-62. doi:
10.1007/s10549-019-05365-y. [PMID: 31346846] - Vardan Nersesjan, Klaus Hansen, Thomas Krag, Morten Duno, Tina D Jeppesen. Palbociclib in combination with simvastatin induce severe rhabdomyolysis: a case report.
BMC neurology.
2019 Oct; 19(1):247. doi:
10.1186/s12883-019-1490-4. [PMID: 31640597] - Hilary E Nicholson, Zeshan Tariq, Benjamin E Housden, Rebecca B Jennings, Laura A Stransky, Norbert Perrimon, Sabina Signoretti, William G Kaelin. HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species.
Science signaling.
2019 10; 12(601):. doi:
10.1126/scisignal.aay0482. [PMID: 31575731] - Yi-Bo Hou, Kunmei Ji, Yue-Tong Sun, Li-Na Zhang, Jia-Jie Chen. CDK4/6 inhibitor palbociclib suppresses IgE-mediated mast cell activation.
Journal of translational medicine.
2019 08; 17(1):276. doi:
10.1186/s12967-019-2026-9. [PMID: 31429774] - Jiaxin Yao, Xu Jiang, Qiao Liu, Xuemei Yuan, Tiantian Feng, Kunjie Li, Longshan Zhao. An available strategy based on accurate mass by ultra high performance liquid chromatography coupled to Fourier transform ion cyclotron resonance mass spectrometry technology to characterization of metabolic profile of palbociclib in rat urine, feces and bile.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2019 Aug; 1124(?):37-46. doi:
10.1016/j.jchromb.2019.05.032. [PMID: 31176268] - Alejandra Martínez-Chávez, Hilde Rosing, Michel Hillebrand, Matthijs Tibben, Alfred H Schinkel, Jos H Beijnen. Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry.
Analytical and bioanalytical chemistry.
2019 Aug; 411(20):5331-5345. doi:
10.1007/s00216-019-01932-w. [PMID: 31209549] - M Jove, J A Spencer, M E Hubbard, E C Holden, R D O'Dea, B S Brook, R M Phillips, S W Smye, P M Loadman, C J Twelves. Cellular Uptake and Efflux of Palbociclib In Vitro in Single Cell and Spheroid Models.
The Journal of pharmacology and experimental therapeutics.
2019 08; 370(2):242-251. doi:
10.1124/jpet.119.256693. [PMID: 31189729] - David Paul, Shruti Surendran, Patheparapu Chandrakala, Nanjappan Satheeshkumar. An assessment of the impact of green tea extract on palbociclib pharmacokinetics using a validated UHPLC-QTOF-MS method.
Biomedical chromatography : BMC.
2019 Apr; 33(4):e4469. doi:
10.1002/bmc.4469. [PMID: 30549069] - David Paul, Patheparapu Chandrakala, Shruti Surendran, Prasanth Bitla, Nanjappan Satheeshkumar. Pharmacokinetic interaction study of novel combination of palbociclib and sorafenib for hepatocellular carcinoma in SD rats.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2019 Feb; 1108(?):25-31. doi:
10.1016/j.jchromb.2019.01.003. [PMID: 30660839] - Cheng-Lung Hsu, Kar-Wai Lui, Lang-Ming Chi, Yung-Chia Kuo, Yin-Kai Chao, Chun-Nan Yeh, Li-Yu Lee, Yenlin Huang, Tung-Liang Lin, Mei-Yuan Huang, Yi-Ru Lai, Yuan-Ming Yeh, Hsien-Chi Fan, An-Chi Lin, Yen-Jung Lu, Chia-Hsun Hsieh, Kai-Ping Chang, Ngan-Ming Tsang, Hung-Ming Wang, Alex Y Chang, Yu-Sun Chang, Hsin-Pai Li. Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.
Journal of experimental & clinical cancer research : CR.
2018 Sep; 37(1):233. doi:
10.1186/s13046-018-0873-5. [PMID: 30236142] - Balasaheb B Chavan, Shristy Tiwari, Shankar G, Rakesh D Nimbalkar, Prabha Garg, Srinivas R, M V N Kumar Talluri. In vitro and in vivo metabolic investigation of the Palbociclib by UHPLC-Q-TOF/MS/MS and in silico toxicity studies of its metabolites.
Journal of pharmaceutical and biomedical analysis.
2018 Aug; 157(?):59-74. doi:
10.1016/j.jpba.2018.05.008. [PMID: 29772457] - Ben O'Leary, Sarah Hrebien, James P Morden, Matthew Beaney, Charlotte Fribbens, Xin Huang, Yuan Liu, Cynthia Huang Bartlett, Maria Koehler, Massimo Cristofanilli, Isaac Garcia-Murillas, Judith M Bliss, Nicholas C Turner. Early circulating tumor DNA dynamics and clonal selection with palbociclib and fulvestrant for breast cancer.
Nature communications.
2018 03; 9(1):896. doi:
10.1038/s41467-018-03215-x. [PMID: 29497091] - Norikazu Masuda, Reiki Nishimura, Masato Takahashi, Kenichi Inoue, Shinji Ohno, Hiroji Iwata, Yuko Mori, Satoshi Hashigaki, Yasuaki Muramatsu, Takashi Nagasawa, Yoshiko Umeyama, Masakazu Toi. Palbociclib in combination with letrozole as first-line treatment for advanced breast cancer: A Japanese phase II study.
Cancer science.
2018 Mar; 109(3):803-813. doi:
10.1111/cas.13507. [PMID: 29345736] - Najla Kfoury, Tao Sun, Kwanha Yu, Nathan Rockwell, Kelsey L Tinkum, Zongtai Qi, Nicole M Warrington, Peter McDonald, Anuradha Roy, Scott J Weir, Carrie A Mohila, Benjamin Deneen, Joshua B Rubin. Cooperative p16 and p21 action protects female astrocytes from transformation.
Acta neuropathologica communications.
2018 02; 6(1):12. doi:
10.1186/s40478-018-0513-5. [PMID: 29458417] - Lei Yin, Heng Li, Wenjian Liu, Zhenglin Yao, Zhenzhen Cheng, Huabei Zhang, Hui Zou. A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy.
European journal of medicinal chemistry.
2018 Jan; 144(?):1-28. doi:
10.1016/j.ejmech.2017.12.003. [PMID: 29247857] - Nusayba Bagegni, Shana Thomas, Ning Liu, Jingqin Luo, Jeremy Hoog, Donald W Northfelt, Matthew P Goetz, Andres Forero, Mattias Bergqvist, Jakob Karen, Magnus Neumüller, Edward M Suh, Zhanfang Guo, Kiran Vij, Souzan Sanati, Matthew Ellis, Cynthia X Ma. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib.
Breast cancer research : BCR.
2017 Nov; 19(1):123. doi:
10.1186/s13058-017-0913-7. [PMID: 29162134] - Wan Sun, Karen J Klamerus, Lisa M Yuhas, Sylvester Pawlak, Anna Plotka, Melissa O'Gorman, Leonid Kirkovsky, Maha Kosa, Diane Wang. Impact of Acid-Reducing Agents on the Pharmacokinetics of Palbociclib, a Weak Base With pH-Dependent Solubility, With Different Food Intake Conditions.
Clinical pharmacology in drug development.
2017 Nov; 6(6):614-626. doi:
10.1002/cpdd.356. [PMID: 28430398] - Sibylle Loibl, Nicholas C Turner, Jungsil Ro, Massimo Cristofanilli, Hiroji Iwata, Seock-Ah Im, Norikazu Masuda, Sherene Loi, Fabrice André, Nadia Harbeck, Sunil Verma, Elizabeth Folkerd, Kathy Puyana Theall, Justin Hoffman, Ke Zhang, Cynthia Huang Bartlett, Mitchell Dowsett. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results.
The oncologist.
2017 09; 22(9):1028-1038. doi:
10.1634/theoncologist.2017-0072. [PMID: 28652278] - Wan Sun, Peter J O'Dwyer, Richard S Finn, Ana Ruiz-Garcia, Geoffrey I Shapiro, Gary K Schwartz, Angela DeMichele, Diane Wang. Characterization of Neutropenia in Advanced Cancer Patients Following Palbociclib Treatment Using a Population Pharmacokinetic-Pharmacodynamic Modeling and Simulation Approach.
Journal of clinical pharmacology.
2017 09; 57(9):1159-1173. doi:
10.1002/jcph.902. [PMID: 28419480] - John E Bisi, Jessica A Sorrentino, Jamie L Jordan, David D Darr, Patrick J Roberts, Francis X Tavares, Jay C Strum. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Oncotarget.
2017 Jun; 8(26):42343-42358. doi:
10.18632/oncotarget.16216. [PMID: 28418845] - Alicja Urbaniak, Magdalena Delgado, Karol Kacprzak, Timothy C Chambers. Activity of resveratrol triesters against primary acute lymphoblastic leukemia cells.
Bioorganic & medicinal chemistry letters.
2017 06; 27(12):2766-2770. doi:
10.1016/j.bmcl.2017.04.066. [PMID: 28499732] - Yanke Yu, Cho-Ming Loi, Justin Hoffman, Diane Wang. Physiologically Based Pharmacokinetic Modeling of Palbociclib.
Journal of clinical pharmacology.
2017 02; 57(2):173-184. doi:
10.1002/jcph.792. [PMID: 27402157] - Charlotte Fribbens, Ben O'Leary, Lucy Kilburn, Sarah Hrebien, Isaac Garcia-Murillas, Matthew Beaney, Massimo Cristofanilli, Fabrice Andre, Sherene Loi, Sibylle Loibl, John Jiang, Cynthia Huang Bartlett, Maria Koehler, Mitch Dowsett, Judith M Bliss, Stephen R D Johnston, Nicholas C Turner. Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2016 09; 34(25):2961-8. doi:
10.1200/jco.2016.67.3061. [PMID: 27269946] - Kenji Tamura, Hirofumi Mukai, Yoichi Naito, Kan Yonemori, Makoto Kodaira, Yuko Tanabe, Noboru Yamamoto, Shozo Osera, Masaoki Sasaki, Yuko Mori, Satoshi Hashigaki, Takashi Nagasawa, Yoshiko Umeyama, Takayuki Yoshino. Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients.
Cancer science.
2016 Jun; 107(6):755-63. doi:
10.1111/cas.12932. [PMID: 26991823] - Massimo Cristofanilli, Nicholas C Turner, Igor Bondarenko, Jungsil Ro, Seock-Ah Im, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Sunil Verma, Hiroji Iwata, Nadia Harbeck, Ke Zhang, Kathy Puyana Theall, Yuqiu Jiang, Cynthia Huang Bartlett, Maria Koehler, Dennis Slamon. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
The Lancet. Oncology.
2016 Apr; 17(4):425-439. doi:
10.1016/s1470-2045(15)00613-0. [PMID: 26947331] - Deepak Perumal, Pei-Yu Kuo, Violetta V Leshchenko, Zewei Jiang, Sai Krishna Athaluri Divakar, Hearn Jay Cho, Ajai Chari, Joshua Brody, M V Ramana Reddy, Weijia Zhang, E Premkumar Reddy, Sundar Jagannath, Samir Parekh. Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma.
Cancer research.
2016 Mar; 76(5):1225-36. doi:
10.1158/0008-5472.can-15-2934. [PMID: 26873845] - Natalia J Sumi, Brent M Kuenzi, Claire E Knezevic, Lily L Remsing Rix, Uwe Rix. Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer.
ACS chemical biology.
2015 Dec; 10(12):2680-6. doi:
10.1021/acschembio.5b00368. [PMID: 26390342] - Karen E Parrish, Jenny Pokorny, Rajendar K Mittapalli, Katrina Bakken, Jann N Sarkaria, William F Elmquist. Efflux transporters at the blood-brain barrier limit delivery and efficacy of cyclin-dependent kinase 4/6 inhibitor palbociclib (PD-0332991) in an orthotopic brain tumor model.
The Journal of pharmacology and experimental therapeutics.
2015 Nov; 355(2):264-71. doi:
10.1124/jpet.115.228213. [PMID: 26354993] - Mark C de Gooijer, Ping Zhang, Nishita Thota, Isabel Mayayo-Peralta, Levi C M Buil, Jos H Beijnen, Olaf van Tellingen. P-glycoprotein and breast cancer resistance protein restrict the brain penetration of the CDK4/6 inhibitor palbociclib.
Investigational new drugs.
2015 Oct; 33(5):1012-9. doi:
10.1007/s10637-015-0266-y. [PMID: 26123925] - Thomas J Raub, Graham N Wishart, Palaniappan Kulanthaivel, Brian A Staton, Rose T Ajamie, Geri A Sawada, Lawrence M Gelbert, Harlan E Shannon, Concepcion Sanchez-Martinez, Alfonso De Dios. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Drug metabolism and disposition: the biological fate of chemicals.
2015 Sep; 43(9):1360-71. doi:
10.1124/dmd.114.062745. [PMID: 26149830] - Noemí Esteras, Carolina Alquézar, Fernando Bartolomé, Ana de la Encarnación, Félix Bermejo-Pareja, José Antonio Molina, Ángeles Martín-Requero. G1/S Cell Cycle Checkpoint Dysfunction in Lymphoblasts from Sporadic Parkinson's Disease Patients.
Molecular neurobiology.
2015 Aug; 52(1):386-98. doi:
10.1007/s12035-014-8870-y. [PMID: 25182869] - Navjotsingh Pabla, Alice A Gibson, Mike Buege, Su Sien Ong, Lie Li, Shuiying Hu, Guoqing Du, Jason A Sprowl, Aksana Vasilyeva, Laura J Janke, Eberhard Schlatter, Taosheng Chen, Giuliano Ciarimboli, Alex Sparreboom. Mitigation of acute kidney injury by cell-cycle inhibitors that suppress both CDK4/6 and OCT2 functions.
Proceedings of the National Academy of Sciences of the United States of America.
2015 Apr; 112(16):5231-6. doi:
10.1073/pnas.1424313112. [PMID: 25848011] - Derek P DiRocco, John Bisi, Patrick Roberts, Jay Strum, Kwok-Kin Wong, Norman Sharpless, Benjamin D Humphreys. CDK4/6 inhibition induces epithelial cell cycle arrest and ameliorates acute kidney injury.
American journal of physiology. Renal physiology.
2014 Feb; 306(4):F379-88. doi:
10.1152/ajprenal.00475.2013. [PMID: 24338822] - Sabine Paternot, Bianca Colleoni, Xavier Bisteau, Pierre P Roger. The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.
Cell cycle (Georgetown, Tex.).
2014; 13(18):2879-88. doi:
10.4161/15384101.2014.946841. [PMID: 25486476] - Joshua E Logan, Nikayeh Mostofizadeh, Amrita J Desai, Erika VON Euw, Dylan Conklin, Veerauo Konkankit, Habib Hamidi, Mark Eckardt, Lee Anderson, Hsiao-Wang Chen, Charles Ginther, Eileen Taschereau, Peter H Bui, James G Christensen, Arie S Belldegrun, Dennis J Slamon, Fairooz F Kabbinavar. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Anticancer research.
2013 Aug; 33(8):2997-3004. doi:
NULL. [PMID: 23898052] - Sadayappan V Rahavendran, Sylvia Vekich, Heather Skor, Minerva Batugo, Leslie Nguyen, Bhasker Shetty, Zhongzhou Shen. Discovery pharmacokinetic studies in mice using serial microsampling, dried blood spots and microbore LC-MS/MS.
Bioanalysis.
2012 May; 4(9):1077-95. doi:
10.4155/bio.12.85. [PMID: 22612688] - Cathy C Zhang, Zhengming Yan, Wenlin Li, Kyle Kuszpit, Cory L Painter, Qin Zhang, Patrick B Lappin, Tim Nichols, Maruja E Lira, Timothy Affolter, Neeta R Fahey, Carleen Cullinane, Mary Spilker, Kenneth Zasadny, Peter O'Brien, Dana Buckman, Anthony Wong, James G Christensen. [(18)F]FLT-PET imaging does not always 'light up' proliferating tumor cells.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2012 Mar; 18(5):1303-12. doi:
10.1158/1078-0432.ccr-11-1433. [PMID: 22170262] - Danielle Smith, Max Tella, Sadayappan V Rahavendran, Zhongzhou Shen. Quantitative analysis of PD 0332991 in mouse plasma using automated micro-sample processing and microbore liquid chromatography coupled with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2011 Oct; 879(27):2860-5. doi:
10.1016/j.jchromb.2011.08.009. [PMID: 21889427] - Leslie Nguyen, Wei-Zhu Zhong, Cory L Painter, Cathy Zhang, Sadayappan V Rahavendran, Zhongzhou Shen. Quantitative analysis of PD 0332991 in xenograft mouse tumor tissue by a 96-well supported liquid extraction format and liquid chromatography/mass spectrometry.
Journal of pharmaceutical and biomedical analysis.
2010 Nov; 53(3):228-34. doi:
10.1016/j.jpba.2010.02.031. [PMID: 20236782] - Cathy Zhang, Zhengming Yan, Maria E Arango, Cory L Painter, Kenna Anderes. Advancing bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-435-HAL-Luc mammary fat pad and subrenal capsule tumor models.
Clinical cancer research : an official journal of the American Association for Cancer Research.
2009 Jan; 15(1):238-46. doi:
10.1158/1078-0432.ccr-08-0897. [PMID: 19118051] - Eline Menu, Josefina Garcia, Xiangao Huang, Maurizio Di Liberto, Peter L Toogood, Isan Chen, Karin Vanderkerken, Selina Chen-Kiang. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
Cancer research.
2008 Jul; 68(14):5519-23. doi:
10.1158/0008-5472.can-07-6404. [PMID: 18632601]